<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01699217</url>
  </required_header>
  <id_info>
    <org_study_id>CML0912</org_study_id>
    <nct_id>NCT01699217</nct_id>
  </id_info>
  <brief_title>Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase</brief_title>
  <acronym>CML0912</acronym>
  <official_title>Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GIMEMA CML Working Party promotes a multicentre, observational, prospective study of CML
      patients treated frontline with NIL. Patients will be followed for 5 years. This study will
      help the definition of guidelines for the treatment of CML patients in early CP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to describe the stability of molecular response with
      NIL as frontline therapy in newly diagnosed, unselected, CP CML patients, in an independent,
      investigator-initiated observational study. Imatinib mesylate (IM), a protein tyrosine kinase
      inhibitor (TKI) targeting BCR-ABL, has become in the last decade the standard of care for
      Chronic Myeloid Leukaemia (CML) in chronic phase (CP)1,2. Nilotinib (NIL) is a second
      generation TKI, effective in IM-resistant and IM-intolerant patients, which demonstrated
      superior efficacy to IM in early CP BCR-ABL+ CML patients3. Currently, the most important
      target of the treatment of CML with TKIs is the major molecular response (MMR), defined as a
      ≥ 3 log reduction in BCR-ABL/ABL transcript level, marker of better long-term outcome. With
      imatinib therapy, achieving a MMR correlates with an improved probability of a durable
      cytogenetic remission30. Results from IRIS suggest that a MMR after 12 months of imatinib
      therapy may be a marker of stable response. Further on, the IRIS study showed that patients
      with a MMR after 12 months of therapy had a significantly better probability of disease-free
      survival compared with those in complete cytogenetic remission, but not in MMR31. Moreover,
      obtaining an undetectable BCR-ABL transcript level is extremely relevant in order to consider
      TKIs discontinuation. This condition is known as &quot;Complete Molecular Response&quot; (CMR) and is
      further defined according to the sensitivity achieved (for the definition see the &quot;Criteria
      of evaluation&quot; section). As far as treatment discontinuation, two experiences have been
      published so far, aimed at evaluating the persistence of the CMR after imatinib
      discontinuation. The first was a pilot study32 where 12 patients were included. These 12
      patients discontinued imatinib after at least 2 years of CMR (median duration of negativity,
      32 months). Six patients displayed a molecular relapse with a detectable BCR-ABL transcript
      at 1, 1, 2, 3, 4, and 5 months. Imatinib was then reintroduced and led to a novel molecular
      response. Six other patients (50%) still have an undetectable level of BCR-ABL transcript
      after a median follow-up of 18 months (range, 9-24 months). The results of this pilot trial
      have been confirmed and extended in a second trial, the STIM trial33: 100 patients were
      enrolled, median follow-up 17 months, 69 patients with at least 12 months follow-up: 42 (61%)
      of these 69 patients relapsed (40 before 6 months, one patient at month 7, and one at month
      19). At 12 months, the probability of persistent CMR for these 69 patients was 41% (95% CI
      29-52). All patients who relapsed responded to reintroduction of imatinib. An increase of the
      CMR rate could possibly translate in a higher proportion of patients candidate to stopping
      anti-CML treatment, with higher probability of remaining disease-free in the long term. The
      advantages of this possible future scenario could be: first, the possibility of treatment
      discontinuation at least in patients with chronic clinical adverse events; second, a
      potential reduction of the costs of TKI treatment (after the introduction of TKI, the costs
      of CML treatment is increasing year by year, with the increasing prevalence of CML patients).
      Standardized molecular monitoring has become widely available in Europe through the efforts
      of EUTOS cooperation19 and now allows for the generation of comparable data on the residual
      disease using recalculation on the international scale despite these data being analyzed in
      many different laboratories. These advances in the standardization of molecular responses and
      the improvement of targeted therapy have allowed for comparable response assessment across
      Italian Centres and early treatment optimization of patients.

      In summary, 1) monitoring of molecular response and of deep and sustained molecular response,
      provides a straightforward opportunity to assess patients' response and possible prognosis in
      the use of targeted therapy. 2) Most data on second generation TKIs are from
      company-sponsored studies generally implemented in selected referral centres. 3) The detailed
      description of the kinetic of the molecular response and, particularly, the rate of stable
      MR4, potentially related in turn with a subsequent treatment discontinuation, within the
      frame of a long-term post-marketing surveillance observational trial offered to all eligible
      patients followed at a nation-wide, independent multicentre group is the core distinctive
      feature of this observational trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of confirmed MR4</measure>
    <time_frame>At 24 months from study entry</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of MMR</measure>
    <time_frame>At 24, 36, 48, and 60 months from study entry.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of MR4</measure>
    <time_frame>At 24, 36, 48, and 60 months from study entry.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of MR4.5</measure>
    <time_frame>At 24, 36, 48, and 60 months from study entry.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of confirmed MR4</measure>
    <time_frame>At 36, 48, and 60 months from study entry.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of stable MR4</measure>
    <time_frame>At 24, 36, 48, and 60 months from study entry</time_frame>
    <description>(at least three PCR results with MR4 within the last year [± 2 months] and no results &gt; 0.01% during the same period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of stable MR4.5</measure>
    <time_frame>At 24, 36, 48, and 60 months from study entry</time_frame>
    <description>(at least three PCR results with MR4.5 within the last year [± 2 months] and no results &gt; 0.0032% during the same period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of confirmed loss of MMR (MR3)</measure>
    <time_frame>At 60 months from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of confirmed loss of MMR</measure>
    <time_frame>At one year from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of Complete Cytogenetic Response</measure>
    <time_frame>At one year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative rate of permanent NIL discontinuation</measure>
    <time_frame>At 5 years from study entry</time_frame>
    <description>(for failure [defined according to ELN recommendations 2009], intolerance, and death for any reason; not for patients in ≥ MR4 entering clinical trials exploring nilotinib discontinuation)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Phase Philadelphia Positive</condition>
  <condition>BCR-ABL Positive</condition>
  <condition>Chronic Myeloid Leukaemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Treatment decision is at the discretion of the investigator and must not be made on the
        basis of this observational study. Patients should have their treatment initiated in
        accordance with the summary of product characteristics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: &gt;=18 years;

          -  Patients with chronic phase Ph+ and/or BCR-ABL+ CML, newly diagnosed (less than 6
             months);

          -  Prior treatment with Hydroxyurea or Anagrelide is allowed;

          -  Prior treatment with IM for less than 30 days is allowed;

          -  Signed written informed const according to ICH/EU/GCP and national local laws.

        Exclusion Criteria:

          -  Patients who are pregnant (negative pregnancy test is requested within 2 days before
             nilotinib start) or breast feeding, or adults of reproductive potential not employing
             an effective method of birth control.

          -  Newly diagnosed Ph+ and/or BCR-ABL+ CML patients in advanced phases (accelerated or
             blastic phase).

          -  Prior treatment with nilotinib, dasatinib, or other tyrosine-kinase inhibitors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianantonio Rosti, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology and Oncological Sciences, S.Orsola-Malpighi Hospital, University of Bologna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi, Dr.</last_name>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Pini, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Massimo Pini, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gioacchino Catania, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Nuovo Ospedale &quot;Torrette&quot;</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serena Rupoli, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Serena Rupoli, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Rita Scortechini, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Area Medica - Presidio Ospedaliero &quot;C. e G.Mazzoni&quot;</name>
      <address>
        <city>Ascoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catia Bigazzi, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Catia Bigazzi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia con trapianto-Università degli Studi di Bari Aldo Moro</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgina Specchia, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Giorgina Specchia, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonella Russo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giannantonio Rosti</last_name>
    </contact>
    <investigator>
      <last_name>Giannantonio Rosti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USD Trapianti di midollo per adulti - Cattedra di Ematologia - Università degli Studi di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Domenico Russo</last_name>
    </contact>
    <investigator>
      <last_name>Domenico Russo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michele Malagola, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale A. Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Quarta, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni Quarta, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariella Girasoli, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL N.8 - Ospedale &quot;A. Businco&quot; - Struttura Complessa di Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilio Usala, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Emilio Usala, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Pina Simula, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Onco-Ematologia - Centro di Ricerca e Formazione ad Alta tecnologia nelle Scienze Biomediche</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Storti, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Sergio Storti, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristiana Gasbarrino, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>US Dipartimentale - Centro per le malattie del sangue - Ospedale Civile - S.Giacomo</name>
      <address>
        <city>Castelfranco Veneto</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Tagariello, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Tagariello, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Sartori, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ezione di Ematologia C.T.M.O. Istituti Ospitalieri</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Lanza, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Lanza, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce Divisione di Ematologia Cuneo</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davide Rapezzi, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Davide Rapezzi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Gallamini, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico di Careggi, Università delgi studi di Firenze</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto BOSI</last_name>
    </contact>
    <investigator>
      <last_name>Alberto BOSI, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonella Gozzini, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Ematologia Ospedali Riuniti Foggia - Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvana Franca, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Silvana Franca, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppina Spinosa, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - DiMI - Università degli Studi di Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Gobbi, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Marco Gobbi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Micaela Bergamaschi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS_AOU San Martino-IST-Ematologia 1-Monoblocco 11°piano- lato ponente</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angelo Michele Carella, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Angelo Michele Carella, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SOC Ematologia e Centro Trasfusionale Ospedale di Ivrea - ASL TO4</name>
      <address>
        <city>Ivrea</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aitoro Soc, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Aitoro Soc, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriella Tomei, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale &quot;Santa Maria Goretti&quot;</name>
      <address>
        <city>Latina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angelo De Blasio, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Angelo De Blasio, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matteo Pacilli, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caterina Musolino, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Caterina Musolino, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabina Russo, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti &quot;Papardo Piemonte&quot;</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maura Brugiatelli, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Maura Brugiatelli, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Nocilli, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Ciceri, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Fabio Ciceri, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Lunghi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Centro Trapianti di Midollo - IRCCS Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Iurlo, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale &quot;A. Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felicetto Ferrara, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Felicetto Ferrara, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Annunziata, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria - Università degli Studi di Napoli &quot;Federico II&quot; - Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrizio Pane, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Fabrizio Pane, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luigia Luciano, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gennaro - ASL Napoli 1</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Mastrullo, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Lucia Mastrullo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Rosaria Esposito, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sez. di Ematologia Clinica Ospedale San Francesco</name>
      <address>
        <city>Nuoro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delia Noli, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Delia Nolo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosario Di Maggio, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2 Prof. Giuseppe Saglio</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanna Rege, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Giovanna Rege, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Fava, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Padova - Ematologia ed Immunologia Clinica</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pietro Semenzato, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Pietro Semenzato, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gianni Binotto, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia con trapianto di midollo - A.U. Policlinico &quot;Paolo Giaccone&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clementina Caracciolo, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Clementina Caracciolo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosario Di, Maggio</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Maddalena Casa di Cura di Alta Specialità Dipartimento Oncologico di III Livello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurizio Musso, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Maurizio Musto, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ferdinando Pozzetto, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti &quot;Villa Sofia-Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diamante Turri, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Diamante Turri, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raimondo Di Bella, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia CTMO Università degli Studi di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Aversa, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Franca Aversa, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Crugnola, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Div. di Ematologia di Muraglia - CTMO Ospedale San Salvatore</name>
      <address>
        <city>Pesaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Visani, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Visani, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Barulli, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Di Lorenzo, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Di Lorenzo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniele Vallisa, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Daniele Vallisa, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Trabacchi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Pisa - Azienda Ospedaliera Pisana - Dipartimento di Oncologia, dei Trapianti e delle nuove Tecnologie in Medicina - Divisione di Ematologia</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Galimberti, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Sara Galimberti, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Baratè, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Oncologico - Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marzia Salvucci, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Marzia Salvucci, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O.&quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Nobile, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Nobile, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno Martino, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Avanzini, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Isabella Capodanno, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Avanzini, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi&quot;</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrizia Tosi, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Patrizia Tosi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Lia Molinari, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia - Centro Oncologico Basilicata</name>
      <address>
        <city>Rionero in Vulture</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pellegrino Musto, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Pellegrino Musto, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Pietrantuono, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera &quot;Sant' Andrea&quot;-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrico Montefusco, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Enrico Montefusco, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raffaele Porrini, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complesso Ospedaliero S. Giovanni Addolorata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Cedrone, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Barbara Anaclerico, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pronto Soccorso e Accettazione Ematologica - Dipartimento Biotecnologie Cellulari ed Ematologia - Università degli Studi di Roma &quot;Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuliana Alimena, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Giuliana Alimena, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Breccia, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Segreteria di Ematologia - S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Atelda Romano, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Atelda Romano, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Azzurra Romero, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S.Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabetta Abruzzese, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Elisabetta Abruzzese, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monika Trawinska, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simona Sica, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Simona Sica, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Federica Sorà, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale Viterbo - Polo Ospedaliero Centrale - Ospedale Di Ronciglione - U.O. di Ematologia</name>
      <address>
        <city>Ronciglione</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Montanaro, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Marco Montanaro, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Celesti, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>S. G. Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla, Pr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonietta Pia, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico &quot; Le Scotte&quot;</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Bocchia, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Monica Bocchia, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marzia Defina, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SS.C. di Oncoematologia - Dipartimento di Medicina Clinica e Sperimentale - Azienda Ospedaliera - S. Maria Di Terni</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Marina Liberati, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Anna Marina Liberati, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Debora Luzi, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrizia Pregno, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Patrizia Pregno, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia - Med.II Div. Presidio Ospedaliero S. Chiara di Trento</name>
      <address>
        <city>Trento</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Vivaldi, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Vivaldi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Guella, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda U.L.S.S.9 - U.O. di Ematologia</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Gherlinzoni, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Filippo Gherlinzoni, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabetta Calistri, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Policlinico Universitario</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Tiribelli, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Mario Tiribelli, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luciana Marin, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Pizzolo, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni Pizzolo, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimiliano Bonifacio, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2012</study_first_submitted>
  <study_first_submitted_qc>October 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2012</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Myeloid Leukaemia</keyword>
  <keyword>Philadelphia positive</keyword>
  <keyword>BCR-ABL positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

